

- 24 Word Count
- 25 Abstract, 248; Total, 5564
- 26 Inserts
- 27 Tables 2, Supplemental Tables, 5
- 28 Figures 5, Supplemental Figures, 2

29 **Abstract**

30 RNA extraction is an essential step for detection and surveillance of common viral pathogens. 31 Currently, sample processing and RNA extraction are costly and rely on proprietary materials 32 that are difficult to acquire, maintain, and safely discard in low-resource settings. We developed 33 an economical RNA extraction and storage protocol that eliminates the use of instrumentation, 34 expensive materials, and cold chain requirements. Through an iterative process, we optimized 35 viral lysis and RNA binding to and elution from glass fiber membranes. Protocol changes were 36 evaluated by testing eluates in virus-specific real-time RT-PCRs (rRT-PCRs). Efficient, non-37 toxic viral lysis was achieved with a sucrose buffer including KCl, proteinase K and carrier 38 RNA. Glass fiber membranes demonstrated concentration-dependent RNA binding of three 39 arthropod-borne RNA viruses (arboviruses): dengue, chikungunya and Oropouche. Membrane 40 binding was significantly increased in an acidic arginine binding buffer. For the clinical 41 evaluation, 36 dengue virus (DENV)-positive serum samples were extracted in duplicate in the 42 optimized protocol and results were compared to a commercial method. DENV RNA was 43 successfully extracted from 71/72 replicates (98.6%) in the extraction packets, and rRT-PCR Ct 44 values correlated between the techniques. Five clinical samples were selected to evaluate 45 ambient-temperature storage up to 7 days on dried glass fiber membranes. DENV RNA was 46 stable at 1, 3 and 7 days post extraction, with a mean difference in eluate RNA concentration of 47 0.14 log10 copies/µL. At a cost of \$0.08 /sample, RNA extraction and storage packets address 48 key limitations to available protocols and may increase capacity for molecular detection of RNA 49 viruses.

50

51 **Keywords:** ribonucleic acid, extraction, dengue virus, molecular testing

52 RNA viruses are the largest group of human viral pathogens and the most common cause of 53 emerging infectious disease outbreaks.^{1, 2} Clinical management and disease containment rely on 54 accurate laboratory diagnosis. For many RNA viruses, molecular methods provide the most 55 sensitive and specific acute-phase diagnostics³⁻⁷, and RNA extraction remains a crucial step in 56 sample preparation that ensures optimal performance of such methods. However, extraction 57 presents many challenges owing to the relative instability of RNA compared to DNA and the 58 presence of RNA degrading enzymes (RNases) and PCR inhibitors in clinical samples.⁸⁻¹⁰ 59 Extraction is generally performed using commercial kits that are costly and rely on proprietary 60 materials that can be difficult to obtain in low-resource settings or emerging markets.^{11, 12} Kits 61 often require the use of dedicated instruments, corrosive and hazardous chemicals, and -80°C 62 storage of the resulting eluate if testing will not be performed within 24 hours.^{8-10, 13, 14} As a 63 result, RNA extraction and storage remain major barriers to the implementation and use of 64 molecular methods in low-resource settings.

65

66 Arboviruses comprise the subset of RNA viruses transmitted by infected arthropod vectors such 67 as mosquitoes and ticks. These have resulted in large, recent outbreaks caused by the 68 introduction of viruses into naïve populations [e.g., chikungunya virus (CHIKV) and Zika virus 69 (ZIKV) in the Americas in 2014-2016]¹⁵⁻¹⁸ or re-emergence of viruses in populations residing in 70 endemic regions [e.g., yellow fever virus (YFV) and dengue virus (DENV)].¹⁹⁻²³ Of the 71 arboviruses, DENV is responsible for the greatest burden of human disease, causing an estimated 100 million symptomatic infections (dengue cases) per year spread over 125 countries.²⁴ Dengue 73 presents with nonspecific, systemic symptoms that cannot be clinically differentiated from other 74 causes of an acute febrile illness, and diagnostic confirmation relies on the availability of

91 100, 50mM Tris-HCl, and 50 mM EDTA), Sodium Dodecyl Sulfate-NaCl, and sucrose buffer) 92 were evaluated for the ability to lyse DENV, followed by completion of RNA extraction in a 93 commercial spin column protocol (QIAamp Viral RNA Mini Kit, Qiagen). SDS-NaCl and 94 sucrose solutions performed similarly, yielding earlier DENV cycle threshold (Ct) values 95 (indicating increased RNA yield) by rRT-PCR (Table S1). To eliminate potential SDS inhibition 96 of downstream molecular testing, sucrose buffer was chosen as the lysis buffer for further 97 experiments. To further enhance RNA recovery and prevent degradation, varying amounts of

120 the packet. Contrived DENV-positive serum samples were lysed and then treated with either

121 amino acid buffer. Although results did not differ significantly, arginine treatment yielded 122 increased RNA recovery, with lower Ct values overall and decreased variability (Figure S1). 123 Based on these data, arginine was chosen for future experiments. To further evaluate the impact 124 of arginine binding buffer, DENV, CHIKV and OROV RNA were added to the membranes in 125 either the sucrose lysis buffer or an arginine buffer (plus ethanol in both cases). Relative to 126 sucrose buffer, the arginine buffer demonstrated lower mean Ct values and decreased variability 127 in Ct values with each membrane (Figure 2A). Ct values were significantly lower with the use of 128 arginine buffer when data from all membranes were evaluated together (Figure 2A), and the 129 relative increase in RNA yield is shown in Figure 2B. 130 131 Following the initial analytical evaluation with purified RNA, arginine buffer was evaluated as a 132 viral lysis buffer in place of sucrose buffer. However, testing with contrived DENV samples 133 resulted in worse RNA recovery (Figure S2A). The arginine buffer was subsequently integrated 134 as a binding buffer that is added after incubation of the sample in lysis buffer. This allowed for 135 both successful viral lysis and improved binding of viral RNA to the packet membrane (Figure 136 S2B). With the addition of the arginine buffer to the procedural workflow, MgCl2 in the sucrose 137 buffer was changed to KCl to harmonize buffer preparations, which had no impact on RNA 138 recovery (Table S4). 139

140 **Final workflow.** Figure 3 shows the final extraction packet workflow. 25μL of serum or plasma 141 is added to a 1.5mL tube with 25μL lysis mixture (2.5μL carrier RNA, 5μL proteinase k and 142 17.5μL lysis buffer). Following ten-minute incubation at ambient temperature, 100μL of amino 143 acid binding buffer and 150μL of 90% ethanol are added to the lysate and mixed thoroughly by

166

167

168 **Discussion**

169 This study presents the development of an alternative, low-cost extraction method compatible 170 with downstream rRT-PCR analysis for arboviral detection. Using the basic packet design of a 171 previous method for viral DNA detection²⁷, we developed and optimized a protocol that greatly 172 improved extraction efficiency for RNA viruses. Our protocol is suitable for implementation in 173 resource-limited settings as it eliminates the need for expensive proprietary materials, hazardous 174 chemicals, or electricity during the extraction process. The final extraction packet protocol has 175 an estimated cost of \$0.08 /sample and successfully detected 98.7% of DENV-positive clinical 176 samples when compared to a commercial robotic extraction system that has an initial cost of 177 USD \$115,000. Clinical samples were collected during two large DENV outbreaks in Paraguay 178 (DENV-1 in 2018, DENV-4 in 2019-2020). Notably, the range of viral loads in samples that 179 were available for extraction in the current study represent 92.7% of all DENV-positive samples 180 with quantifiable viral loads from these two large outbreaks (Ref. 28, DENV-1; manuscript in 181 progress, DENV-4). Samples with viral loads outside of this range were no longer available for 182 extraction. These data indicate the potential utility of extraction packets in a real-world testing 183 scenario outside of a high resource research laboratory.

184

185 In addition to examining the limitations posed by RNA extraction methods, in this study we 186 address the temperature constraints of common RNA storage procedures. Existing 187 methodologies require ultra-low storage temperatures that are costly to maintain and have limited 188 capacity.^{8, 13, 14} In addition, the need for cold chain storage complicates the shipment of samples 189 from collection sites to reference laboratories. We report an alternative ambient temperature

197

198 To-date, there are few RNA extraction methods suitable for implementation in low-resource 199 communities, none of which evaluate a system comparable to the extraction packet design.³⁰⁻³² 200 Various efforts to provide a sustainable alternative to expensive commercial kits utilize magnetic 201 bead technology or solid-phase extraction methods that include biohazardous reagents. Magnetic 202 bead technologies provide adjustable surface chemistries and ease of use for nucleic acid 203 isolation.³² However, beads are relatively expensive and may be difficult to acquire and 204 implement in limited resource settings. Other solid phase alternatives rely on toxic phenol and/or 205 guanidine-based solutions that inhibit downstream molecular testing and require special handling 206 in the laboratory.³³⁻³⁵ To both reduce inhibitory reagents in the procedure and utilize safer 207 reagents for distribution outside of standard molecular laboratories, we assessed an alternative 208 sucrose-based lysis buffer. Sucrose solutions have been used in various DNA and RNA isolation 209 protocols and have demonstrated a key role in increasing yield of extracted nucleic material and 210 RNA stability, without compromising testing integrity.^{36, 37} The RNA packet extraction protocol 211 provides a simple alternative that relies on easily accessible reagents, including proteinase K, and 212 can be prepared on site in a field setting.

213

214 In addition to the sucrose buffer, amino acid buffers were also examined as alternative lysis 215 solutions to be used in lieu of chaotropic salts. A previous study found that several amino acid 216 solutions provide favorable alternatives to standard buffers for nucleic acid recovery due to 217 interactions between the amino acid, RNA and silica surface.³⁸ Positively charged arginine and 218 polar uncharged glutamine were chosen for evaluation within the extraction packet protocol for 219 their distinct chemical properties. In the RNA extraction packets, low-pH arginine buffer 220 improved RNA yield. However, promising analytical findings did not translate to improved 221 DENV RNA recovery from contrived samples when arginine buffer replaced the optimized 222 sucrose buffer in our extraction protocol. A combined protocol, integrating the arginine solution 223 as a binding buffer after lysis in sucrose buffer, leveraged the properties of both solutions. These 224 data demonstrate the applicability of amino acid buffers in RNA extraction protocols and 225 highlight the importance of rigorous clinical evaluation for findings obtained under optimal 226 laboratory conditions.

227

228 Limitations of the current study include the use of serum and plasma with the extraction packets. 229 These typically require centrifugation for preparation, though represent the most common 230 specimen types for DENV diagnostic testing.^{4, 7, 13, 39, 40} The use of carrier RNA and proteinase K 231 within the lysis mixture also require cold storage following reconstitution, but both reagents can 232 be shipped and stored in a lyophilized format. To address these limitations, future studies should 233 evaluate adaptations to the extraction packets for use with whole blood and alternative methods 234 for ambient temperature storage of carrier RNA and proteinase K.

235

236 Access to reliable and economical RNA extraction methods remains a significant barrier to viral 237 molecular detection and surveillance. The packets developed during this study provide safe, 238 economical, and reproducible RNA extraction from clinical samples. These RNA extraction and 239 storage packets address key limitations to available protocols and may increase capacity for 240 molecular detection of RNA viruses.

241

242

243 **Methods**

244 **Packet design.** The initial physical design of the packet was based on the filtration isolation of 245 nucleic acids (FINA) method, as previously described.²⁷ Basic packet design consisted of a 246 5.56mm diameter membrane disk, sandwiched between a square blotter pad base (2.5 x 2.5 cm; 247 VWR International, Radnor, PA) and a Parafilm cover with a 3.96mm diameter opening 248 (Research Products International, Mt. Prospect, IL) centered directly above the membrane disk 249 (Figure 1). Packets were assembled with Whatman 3, Fusion 5, and glass microfiber (GF/D) 250 membranes (all from MiliporeSigma, Burlington, MA). The initial extraction protocol consisted 251 of 1) incubating 25μL of serum/plasma with a lysis mixture for 10 minutes, 2) addition of 252 ethanol, 3) addition of the lysate-ethanol mixture to the extraction packet, 4) a single wash with 253 100μL 10X glycine solution (pH 2.7; Polysciences, Warrington, PA), and 5) elution of RNA by 254 transfer of the membrane to a 1.5mL tube containing 50μL10mM TE buffer, pH 8.0 (Teknova, 255 Hollister, CA). Membranes were incubated in TE for one minute and subsequently removed and 256 disposed. Eluates were tested immediately by rRT-PCR or stored at 4° C for up to 24 hours.

257

258 **Lysis and binding buffers.** Four experimental lysis buffers were evaluated: deionized water, 259 STET (8% Sucrose, 5% Triton™ X-100, 50mM Tris-HCl, and 50 mM EDTA; Teknova, Hollister, 260 CA), Sodium Dodecyl Sulfate-NaCl, 34 and a sucrose buffer. 36 Lysis buffers were initially 261 incorporated into and evaluated with a membrane-based commercial protocol (QiaAMP Viral 262 RNA Mini Kit, Qiagen, Germantown, MD). Contrived DENV samples were either lysed with 263 buffer AVL (as part of the kit) or an experimental lysis buffer and then extracted with the 264 remaining steps in the manufacturer's protocol. Based on these experiments, the sucrose solution 265 was chosen for the lysis buffer. Poly-A carrier RNA (2.5μg/sample, Qiagen, Germantown, MD) 266 and proteinase K (5μg/sample; New England Biolabs, Ipswich, MA) were evaluated as 267 additional components to the lysis mixture. Further experiments used 25µL/reaction of lysis 268 mixture containing 17.5μL of lysis buffer, 2.5μL (2.5μg) carrier RNA and 5μL (5.0μg) 269 proteinase K. All sucrose solution components were adjusted in an iterative manner for further 270 optimization. NaCl, MgCl₂, and KCl were evaluated as different chaotropic salts across a range 271 of concentrations (50mM to 400mM) alongside varying sucrose concentrations (50mM to 272 300mM). Solution pH was also evaluated at neutral and slightly alkaline pH values (7.0, 7.5, and 273 8.0). The optimized sucrose lysis buffer contained 100mM sucrose (1.2 M; Boston BioProducts, 274 Ashland, MA); 50mM Tris-HCL, pH 7.0; 100mM KCl (both from MilliporeSigma, USA). 275

276 Arginine and glutamine amino acid binding buffers were initially prepared as described.⁴¹ The 277 buffer contained 100mM L-arginine (MilliporeSigma, USA) and 400 mM KCl. Binding buffer 278 pH was optimized across a range from 1.5-9.1, with a final buffer pH of 1.5. Lysis and binding 279 buffers were stored at room temperature. Following preparation, the lysis mixture was used 280 immediately or stored at 4°C until use.

281

293

294 For the stability study, 5 DENV-1 samples with sufficient remaining volume were individually 295 re-extracted with the packets to evaluate RNA stability on days 0, 1, 3, and 7 post extraction. For 296 this evaluation, 8 extraction packets were prepared, with duplicate packets for each time point. 297 On day 0, DENV RNA was completely extracted, eluted off two membranes, and run in the 298 DENV multiplex rRT-PCR to establish a baseline reference. For the remainder of the time 299 points, DENV RNA was extracted with the packets through the glycine wash step and 300 transferred to empty 1.5mL tubes to air dry at ambient temperature for 1 hour. After drying, 301 tubes were closed and stored in airtight plastic bags with desiccant packets. RNA was eluted 302 from dried membranes with 50µL TE buffer on days 1, 3, and 7 following extractions. Eluates 303 were run in the DENV multiplex rRT-PCR for comparison with day 0 results. A four-point

304 standard curve was included on each run to calculate DENV-1 RNA concentration at each time 305 point.^{42, 43}

306

- 327 student's t test (GraphPad Prism version 9.2, GraphPad, San Diego, CA). Graphs were prepared
- 328 with GraphPad and Excel.

329 **Acknowledgements**

- 330 This research was supported by the Doris Duke Foundation (Clinical Scientist Development
- 331 Award 2019089) and the National Institute of Allergy and Infectious Diseases (R21AI146443).
- 332 We thank all members of the research team at the Instituto de Investigaciones en Ciencias de la
- 333 Salud, Universidad Nacional de Asunción, and the participants and their family members who
- 334 have contributed to ongoing studies of arboviral infections in Paraguay. We also thank Katherine
- 335 Immergluck, Maxwell Su, and Victoria Stittleburg at Emory University for their assistance over
- 336 the course of this project.

337 **References**

338 1. Carrasco-Hernandez, R.; Jácome, R.; López Vidal, Y.; Ponce De León, S., Are RNA Viruses
339 Candidate Agents for the Next Global Pandemic? A Review. ILAR Journal 2017, 58 (3), 343-358. 339 Candidate Agents for the Next Global Pandemic? A Review. *ILAR Journal* **2017,** *58* (3), 343-358.

340 2. Rosenberg, R., Detecting the emergence of novel, zoonotic viruses pathogenic to humans. 341 *Cellular and Molecular Life Sciences* **2015,** *72* (6), 1115-1125.

- 342 3. Natrajan, M. S.; Rojas, A.; Waggoner, J. J., Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus. Journal of clinical microbiology 2019. 343 Chikungunya Virus. *Journal of clinical microbiology* **2019**.
- 344 4. Rojas, A.; Cardozo, F.; Cantero, C.; Stittleburg, V.; Lopez, S.; Bernal, C.; Gimenez Acosta, F. 345 E.; Mendoza, L.; Pinsky, B. A.; Arevalo de Guillen, I.; Paez, M.; Waggoner, J., Characterization of 346 dengue cases among patients with an acute illness, Central Department, Paraguay. *PeerJ* **2019,** *7*, e7852.
- 347 5. Waggoner, J. J.; Pinsky, B. A., Zika Virus: Diagnostics for an Emerging Pandemic Threat.
348 *Journal of clinical microbiology* 2016, 54 (4), 860-7. 348 *Journal of clinical microbiology* **2016,** *54* (4), 860-7.
- 349 6. Waggoner, J. J.; Rojas, A.; Pinsky, B. A., Yellow Fever Virus: Diagnostics for a Persistent 350 Arboviral Threat. *Journal of clinical microbiology* **2018,** *56* (10).
- 351 7. World Health Organization, *Dengue: guidelines for diagnosis, treatment, prevention and control*. 352 WHO Press: France, 2009.
- 353 8. Fabre, A. L.; Colotte, M.; Luis, A.; Tuffet, S.; Bonnet, J., An efficient method for long-term room temperature storage of RNA. *Eur J Hum Genet* 2014, 22 (3), 379-85. 354 room temperature storage of RNA. *Eur J Hum Genet* **2014,** *22* (3), 379-85.
- 355 9. Paul, R.; Ostermann, E.; Wei, Q., Advances in point-of-care nucleic acid extraction technologies 356 for rapid diagnosis of human and plant diseases. *Biosens Bioelectron* **2020,** *169*, 112592.
- 357 10. Tan, S. C.; Yiap, B. C., DNA, RNA, and protein extraction: the past and the present. *J Biomed* 358 *Biotechnol* **2009,** *2009*, 574398.
- 359 11. Domingo, C.; Niedrig, M.; Teichmann, A.; Kaiser, M.; Rumer, L.; Jarman, R. G.; Donoso-360 Mantke, O., 2nd international external quality control assessment for the molecular diagnosis of Dengue 361 infections. *PLoS neglected tropical diseases* **2010,** *4* (10), e833.
- 362 12. Satyanarayana, M., Material shortages hamper testing for novel coronavirus. *C&EN* **2020,** *98* $(12), 6.$
- 364 13. Centers for Disease Control and Prevention, CDC DENV-1-4 Real-Time RT-PCR Assay: 365 Instructions for Use. 2013.
- 366 14. Centers for Disease Control and Prevention, Trioplex Real-time RT-PCR Assay: Instructions for 367 Use. 2021.
- 368 15. Charrel, R. N.; Leparc-Goffart, I.; Gallian, P.; de Lamballerie, X., Globalization of Chikungunya: 10 years to invade the world. Clinical microbiology and infection : the official
- 369 Chikungunya: 10 years to invade the world. *Clinical microbiology and infection : the official publication*
- 370 *of the European Society of Clinical Microbiology and Infectious Diseases* **2014,** *20* (7), 662-3.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.01.28.22270041;](https://doi.org/10.1101/2022.01.28.22270041) this version posted January 31, 2022. The copyright holder for this preprint

- 371 16. Weaver, S. C.; Lecuit, M., Chikungunya virus and the global spread of a mosquito-borne disease.
372 The New England journal of medicine 2015, 372 (13), 1231-9. 372 *The New England journal of medicine* **2015,** *372* (13), 1231-9.
- 373 17. Musso, D.; Gubler, D. J., Zika Virus. *Clinical microbiology reviews* **2016,** *29* (3), 487-524.

374 18. Waggoner, J. J.; Pinsky, B. A., How great is the threat of chikungunya virus? *Expert review of* 375 *anti-infective therapy* **2015,** *13* (3), 291-3.

- 376 19. Bhatt, S.; Gething, P. W.; Brady, O. J.; Messina, J. P.; Farlow, A. W.; Moyes, C. L.; Drake, J.
- 377 M.; Brownstein, J. S.; Hoen, A. G.; Sankoh, O.; Myers, M. F.; George, D. B.; Jaenisch, T.; Wint, G.
- 378 R.; Simmons, C. P.; Scott, T. W.; Farrar, J. J.; Hay, S. I., The global distribution and burden of dengue.
379 Nature 2013, 496 (7446), 504-7. 379 *Nature* **2013,** *496* (7446), 504-7.
- 380 20. Guzman, M. G.; Harris, E., Dengue. *Lancet* **2015,** *385* (9966), 453-65.
- 381 21. Shepard, D. S.; Undurraga, E. A.; Halasa, Y. A.; Stanaway, J. D., The global economic burden 382 of dengue: a systematic analysis. *The Lancet. Infectious diseases* **2016**.
- 383 22. Zhao, S.; Stone, L.; Gao, D.; He, D., Modelling the large-scale yellow fever outbreak in Luanda, 384 Angola, and the impact of vaccination. *PLoS neglected tropical diseases* **2018,** *12* (1), e0006158.
- 385 23. Dexheimer Paploski, I. A.; Souza, R. L.; Tauro, L. B.; Cardoso, C. W.; Mugabe, V. A.; Pereira 386 Simoes Alves, A. B.; de Jesus Gomes, J.; Kikuti, M.; Campos, G. S.; Sardi, S.; Weaver, S. C.; Reis, 387 M. G.; Kitron, U.; Ribeiro, G. S., Epizootic Outbreak of Yellow Fever Virus and Risk for Human 388 Disease in Salvador, Brazil. *Annals of internal medicine* **2017**.
- 389 24. Messina, J. P.; Brady, O. J.; Golding, N.; Kraemer, M. U. G.; Wint, G. R. W.; Ray, S. E.; 390 Pigott, D. M.; Shearer, F. M.; Johnson, K.; Earl, L.; Marczak, L. B.; Shirude, S.; Davis Weaver, N.; 391 Gilbert, M.; Velayudhan, R.; Jones, P.; Jaenisch, T.; Scott, T. W.; Reiner, R. C.; Hay, S. I., The current and future global distribution and population at risk of dengue. *Nature Microbiology* 2019, 4 (9), 1508-392 and future global distribution and population at risk of dengue. *Nature Microbiology* **2019,** *4* (9), 1508- 1515.
- 394 25. Rojas, A.; Aria, L.; de Guillen, Y. A.; Acosta, M. E.; Infanzón, B.; Diaz, V.; López, L.;
- 395 Meza, T.; Riveros, O., Perfil clínico, hematológico y serológico en pacientes con sospecha de dengue del
396 HICS-UNA, 2009-2013. *Mem Inst Investig Cienc Salud* 2016, 14 (2), 68-74. 396 IICS-UNA, 2009-2013. *Mem Inst Investig Cienc Salud* **2016,** *14* (2), 68-74.
- 397 26. Balmaseda, A.; Hammond, S. N.; Tellez, Y.; Imhoff, L.; Rodriguez, Y.; Saborio, S. I.; 398 Mercado, J. C.; Perez, L.; Videa, E.; Almanza, E.; Kuan, G.; Reyes, M.; Saenz, L.; Amador, J
- 398 Mercado, J. C.; Perez, L.; Videa, E.; Almanza, E.; Kuan, G.; Reyes, M.; Saenz, L.; Amador, J. J.;
- 399 Harris, E., High seroprevalence of antibodies against dengue virus in a prospective study of
- 400 schoolchildren in Managua, Nicaragua. *Tropical medicine & international health : TM & IH* **2006,** *11* (6), 935-42.
- 402 27. McFall, S. M.; Wagner, R. L.; Jangam, S. R.; Yamada, D. H.; Hardie, D.; Kelso, D. M., A
403 simple and rapid DNA extraction method from whole blood for highly sensitive detection and 403 simple and rapid DNA extraction method from whole blood for highly sensitive detection and
404 quantitation of HIV-1 proviral DNA by real-time PCR. Journal of virological methods 2015, 2
- 404 quantitation of HIV-1 proviral DNA by real-time PCR. *Journal of virological methods* **2015,** *214*, 37-42.
- 405 28. Seyhan, A. A.; Burke, J. M., Mg2+-independent hairpin ribozyme catalysis in hydrated RNA 406 films. *RNA* **2000,** *6* (2), 189-98.
- 407 29. Perreault, D. M.; Ansly, E. V., Unifying the Current Data on the Mechanism of Cleavage 408 Transesterification of RNA. *Angew. Clrem. Int. Ed. Eng.* **1997,** *36*, 432-450.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.01.28.22270041;](https://doi.org/10.1101/2022.01.28.22270041) this version posted January 31, 2022. The copyright holder for this preprint

409 30. Han, P.; Go, M. K.; Chow, J. Y.; Xue, B.; Lim, Y. P.; Crone, M. A.; Storch, M.; Freemont, P. 410 S.; Yew, W. S., A high-throughput pipeline for scalable kit-free RNA extraction. *Scientific Reports* **2021,** 411 *11* (1).

- 412 31. Wozniak, A.; Cerda, A.; Ibarra-Henríquez, C.; Sebastian, V.; Armijo, G.; Lamig, L.; Miranda, 413 C.; Lagos, M.; Solari, S.; Guzmán, A. M.; Quiroga, T.; Hitschfeld, S.; Riveras, E.; Ferrés, M.;
- 414 Gutiérrez, R. A.; García, P., A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR. 415 *Scientific Reports* **2020,** *10* (1).
- 416 32. Pearlman, S. I.; Leelawong, M.; Richardson, K. A.; Adams, N. M.; Russ, P. K.; Pask, M. E.;
- 417 Wolfe, A. E.; Wessely, C.; Haselton, F. R., Low-Resource Nucleic Acid Extraction Method Enabled by
418 High-Gradient Magnetic Separation. ACS Applied Materials & Interfaces 2020, 12 (11), 12457-12467.
- 418 High-Gradient Magnetic Separation. *ACS Applied Materials & Interfaces* **2020,** *12* (11), 12457-12467.
- 419 33. Yaffe, H.; Buxdorf, K.; Shapira, I.; Ein-Gedi, S.; Moyal-Ben Zvi, M.; Fridman, E.; 420 Moshelion, M.; Levy, M., LogSpin: a simple, economical and fast method for RNA isolation fi Moshelion, M.; Levy, M., LogSpin: a simple, economical and fast method for RNA isolation from 421 infected or healthy plants and other eukaryotic tissues. *BMC research notes* **2012,** *5*, 45.
- 422 34. Nwokeoji, A. O.; Kilby, P. M.; Portwood, D. E.; Dickman, M. J., RNASwift: A rapid, versatile 423 RNA extraction method free from phenol and chloroform. Anal Biochem 2016, 512, 36-46. 423 RNA extraction method free from phenol and chloroform. *Anal Biochem* **2016,** *512*, 36-46.
- 424 35. Seok, Y.; Batule, B. S.; Kim, M. G., Lab-on-paper for all-in-one molecular diagnostics 425 (LAMDA) of zika, dengue, and chikungunya virus from human serum. *Biosens Bioelectron* **2020,** *165*, 112400.
- 427 36. Berendzen, K.; Searle, I.; Ravenscroft, D.; Koncz, C.; Batschauer, A.; Coupland, G.; 428 Somssich, I. E.; Ulker, B., A rapid and versatile combined DNA/RNA extraction protocol and its Somssich, I. E.; Ulker, B., A rapid and versatile combined DNA/RNA extraction protocol and its 429 application to the analysis of a novel DNA marker set polymorphic between Arabidopsis thaliana 430 ecotypes Col-0 and Landsberg erecta. *Plant Methods* **2005,** *1* (1), 4.
- 431 37. Anjam, M. S.; Ludwig, Y.; Hochholdinger, F.; Miyaura, C.; Inada, M.; Siddique, S.; Grundler, 432 F. M. W., An improved procedure for isolation of high-quality RNA from nematode-infected Arabidopsis 432 F. M. W., An improved procedure for isolation of high-quality RNA from nematode-infected Arabidopsis roots through laser capture microdissection. *Plant Methods* 2016, 12 (1). 433 roots through laser capture microdissection. *Plant Methods* **2016,** *12* (1).
- 434 38. Vandeventer, P. E.; Mejia, J.; Nadim, A.; Johal, M. S.; Niemz, A., DNA Adsorption to and 435 Elution from Silica Surfaces: Influence of Amino Acid Buffers. *The Journal of Physical Chemistry B* 436 **2013,** *117* (37), 10742-10749.
- 437 39. Waggoner, J. J.; Gresh, L.; Mohamed-Hadley, A.; Balmaseda, A.; Soda, K. J.; Abeynayake, J.; 438 Sahoo, M. K.; Liu, Y.; Kuan, G.; Harris, E.; Pinsky, B. A., Characterization of Dengue Virus Infections 439 Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua. *The* 440 *Journal of infectious diseases* **2017,** *215* (12), 1816-1823.
- 441 40. Waggoner, J. J.; Gresh, L.; Vargas, M. J.; Ballesteros, G.; Tellez, Y.; Soda, K. J.; Sahoo, M. 442 K.; Nunez, A.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Viremia and Clinical Presentation in K.; Nunez, A.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Viremia and Clinical Presentation in 443 Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. *Clinical infectious* 444 *diseases : an official publication of the Infectious Diseases Society of America* **2016,** *63* (12), 1584-1590.
- 445 41. Vandeventer, P. E.; Mejia, J.; Nadim, A.; Johal, M. S.; Niemz, A., DNA adsorption to and 446 elution from silica surfaces: influence of amino acid buffers. *J Phys Chem B* **2013,** *117* (37), 10742-9.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.01.28.22270041;](https://doi.org/10.1101/2022.01.28.22270041) this version posted January 31, 2022. The copyright holder for this preprint

- 447 42. Waggoner, J. J.; Abeynayake, J.; Sahoo, M. K.; Gresh, L.; Tellez, Y.; Gonzalez, K.;
- 448 Ballesteros, G.; Guo, F. P.; Balmaseda, A.; Karunaratne, K.; Harris, E.; Pinsky, B. A., Comparison of
- 449 the FDA-approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed
450 assay for dengue virus detection and serotyping. Journal of clinical microbiology 2013, 51 (10), 3418
- 450 assay for dengue virus detection and serotyping. *Journal of clinical microbiology* **2013,** *51* (10), 3418-20.
- 451 43. Waggoner, J. J.; Abeynayake, J.; Sahoo, M. K.; Gresh, L.; Tellez, Y.; Gonzalez, K.;
- 452 Ballesteros, G.; Pierro, A. M.; Gaibani, P.; Guo, F. P.; Sambri, V.; Balmaseda, A.; Karunaratne, K.;
- 453 Harris, E.; Pinsky, B. A., Single-reaction, multiplex, real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses. *PLoS neglected tropical diseases* 2013, 7(4), e2116.
- 454 serotyping of dengue viruses. *PLoS neglected tropical diseases* **2013,** *7* (4), e2116.
- 455 44. Waggoner, J. J.; Gresh, L.; Mohamed-Hadley, A.; Ballesteros, G.; Davila, M. J.; Tellez, Y.; 456 Sahoo, M. K.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Single-Reaction Multiplex Reverse
- 456 Sahoo, M. K.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Single-Reaction Multiplex Reverse
457 Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerging infec*
- 457 Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerging infectious*
- 458 *diseases* **2016,** *22* (7), 1295-7.
- 459 45. Rojas, A.; Stittleburg, V.; Cardozo, F.; Bopp, N.; Cantero, C.; Lopez, S.; Bernal, C.;
- 460 Mendoza, L.; Aguilar, P.; Pinsky, B. A.; Guillen, Y.; Paez, M.; Waggoner, J. J., Real-time RT-PCR for
- 461 the detection and quantitation of Oropouche virus. *Diagnostic microbiology and infectious disease* **2020,**
- 462 *96* (1), 114894.

463

464 **Figures**

- 466 **Figure 1.** Components and assembly of RNA extraction packets (left) and an assembled packet
- 467 (right). Whatman 3, Fusion 5, and GF/D were evaluated as RNA binding membranes.

468 **Figure 2.** Amino acid binding buffers improve RNA yield from RNA extraction packets. **A**) 469 Arginine binding buffer resulted in lower and more consistent rRT-PCR Ct values (improved 470 RNA yield) following DENV, CHIKV and OROV RNA binding to and elution from extraction 471 packets assembled with Whatman 3, Fusion 5, and GF/D membranes. Ct values were 472 significantly lower when results from all membranes were pooled (Total; unpaired t-test); 473 comparisons for individual membranes did not reach statistical significance. Box-and-whisker 474 plots display median and range of all values. **B**) Fold increase in RNA yield with the use of 475 arginine binding buffer compared to lysis buffer. Estimated based on expected 3.3 cycle 476 *decrease* in Ct value for each 10-fold *increase* in RNA concentration in an rRT-PCR with 100% 477 efficiency.

478

- 479 **Figure 3.** Optimized packet workflow for RNA extraction and storage. All steps are performed
- 480 at ambient temperature.

481 **Figure 4.** DENV RNA was successfully extracted from clinical samples using economical

482 packets and rRT-PCR Ct values correlated with results following EMAG robotic extractions.

483 Successful RNA extraction was defined as a positive result in the DENV multiplex $rRT-PCR$.^{42,}

484 ⁴³ Average Ct values from duplicate packet extractions are graphed versus the Ct following

485 EMAG extraction for 36 serum samples positive for DENV-1 (n=20) and DENV-4 (n=16).

486 71/72 eluates (98.6%) from the packets had detectable DENV RNA. The sample from which 1 of

487 2 replicates was positive is displayed as a half-filled circle.

488

489 **Figure 5.** DENV RNA stored on dried extraction membranes is stable at ambient temperature for 490 up to 7 days. **A**) Average DENV-1 RNA concentration in eluates from RNA extraction packets 491 performed in duplicate is displayed for 5 clinical samples that were fully extracted on day 0 or 492 that underwent lysis, addition to GF/D membrane-containing packets, glycine wash, drying and 493 storage at ambient temperature. RNA was then eluted off the dried membranes and tested by 494 rRT-PCR on days 1, 3 and 7. DENV RNA concentration was calculated from a 4-point standard 495 curve included on each run. **B**) Change in RNA concentration between day 0 and days 1, 3, and 496 7. The shaded region highlights the expected intra-run variability of rRT-PCR $(\pm 0.5 \log_{10}$ 497 copies/ μ L). Mean change in concentration across time points (-0.04 log₁₀ copies/ μ L) is displayed 498 (red dashed line).

499 **Table 1.** rRT-PCR Ct values for RNA of different arboviruses following binding to and elution

500 from Whatman 3, Fusion 5, and GF/D membranes.

501 Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; OROV, Oropouche virus

502 ^a Extraction failed, no Ct value

503 **Table 2.** Clinical and DENV laboratory data for 36 clinical samples extracted with the RNA

504 packets.

515 Abbreviations: DENV, dengue virus; SD, standard deviation

516 \textdegree ^a Viral load expressed as log₁₀ copies/mL serum

Simple and economical RNA extraction and storage packets for viral detection from serum

or plasma

Supplemental Material

Sarah Hernandez, Fátima Cardozo, David R. Myers, Alejandra Rojas, Jesse J. Waggoner

Figure S1. rRT-PCR cycle threshold (Ct) values for lysed DENV-positive serum samples treated with glutamine versus arginine binding buffer prior to addition to extraction packets. All evaluations were done with glass fiber GF/D membranes. Ct values were not significantly different for samples treated with arginine (mean, 35.51; standard deviation, 1.15) versus glutamine (36.21; 1.64; $p = 0.2$).

Figure S2. A) Use of arginine buffer for viral lysis results in reduced RNA yield from extraction packets. **B**) A combined protocol incorporating arginine buffer as a binding buffer after lysis in sucrose buffer results in increased RNA yield compared to an extraction protocol without a binding buffer. Different contrived samples were used on the two runs.

Figure S3. Stability of DENV Ct values from 5 clinical samples that were eluted from packets after complete extraction on day 0 or following storage at ambient temperature on the membranes prior to elution on days 1, 3, and 7. Ct values are averages of duplicate extractions tested in the DENV multiplex rRT-PCR. Sample numbers are displayed on the x-axis.

Table S1. Comparison of DENV Ct values following RNA extraction in experimental lysis

buffers.

^a Guanidine thiocyanate-based lysis buffer in the QIAamp Viral RNA Mini Kit

b 8% Sucrose, 5% Triton™ X-100, 50mM Tris-HCl, and 50 mM EDTA

Table S2. Comparison of DENV Ct values following RNA extraction in lysis mixtures with and

without carrier RNA.

a "-" indicates not tested

Table S3. Comparison of DENV Ct values following RNA extraction in lysis mixtures with and

without proteinase K.

a "-" indicates not tested

Table S4. Comparison of DENV Ct values following extractions using sucrose lysis buffer

containing 100mM MgCl₂ or KCl.

Table S5. Ct values following RNA extraction with economical packets and a commercial

robotic system.

* Indicates failed extraction

Abbreviations: EMAG, commercial extraction robot

